Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion description "[The long-term benefits of a finite course of interferon ? (IFN) therapy include a sustained and cumulative response, as well as a reduction in the progression of fibrosis and in the development of cirrhosis and/or HCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion evidence source_evidence_literature NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion SIO_000772 23286854 NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion wasDerivedFrom befree-20140225 NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion wasGeneratedBy ECO_0000203 NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- befree-20140225 importedOn "2014-02-25" NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.